Abacavir 600 mg + Lamivudine 300 mg

,

Abacavir 600 mg + Lamivudine 300 mg

Fixed-dose combination of Abacavir 600 mg and Lamivudine 300 mg for HIV-1 treatment, part of first-line NRTI regimen.

Form: Film-coated tablet

Manufacturer: Cipla Ltd.

Country of Origin: India

Overview

Abamune-L Tablet contains Abacavir 600 mg and Lamivudine 300 mg, two NRTIs used together in HIV-1 combination therapy to inhibit reverse transcriptase and reduce viral replication.

Mechanism of Action

Both Abacavir and Lamivudine act as nucleoside reverse transcriptase inhibitors, blocking the enzyme required for viral DNA synthesis and inhibiting HIV replication. ([turn0search0], [turn0search2])

Dosage & Administration

Take one tablet once daily at the same time each day, with or without food. Do not split or crush the tablet. ([turn0search11])

Side Effects & Precautions

  • Common: headache, fatigue, nausea, rash, fever.
  • Serious: hypersensitivity reactions—HLA-B*5701 screening is recommended before initiating Abacavir. Use caution in pregnancy and avoid alcohol. Monitor hepatic function regularly.

Disclaimer

For product listing purposes only. This information is not a substitute for medical advice. Always follow healthcare provider instructions.

Composition

Abacavir 600 mg + Lamivudine 300 mg

Pack Size

Strip of 30 tablets

Form

Film-coated tablet

Administration Route

Oral (with or without food)

Dosage Regimen

as prescribed, One tablet once daily

Usage Indications

HIV-1 infection (as part of combination ART)

Country of Origin

India

Manufacturer

Cipla Ltd.

Prescription Status

Rx required

Storage Conditions

dry place, Store below 25 °C in a cool

Shelf Life

24 months (typical)

Common Side Effects

fatigue, fever, headache, hypersensitivity reactions, nausea, rash

Precautions

HLA-B*5701 screening recommended; avoid in pregnancy unless benefits outweigh risks; avoid alcohol; monitor liver function

Reviews

There are no reviews yet.

Be the first to review “Abacavir 600 mg + Lamivudine 300 mg”

Your email address will not be published. Required fields are marked *

Requirement List
Scroll to Top